Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Novel CAR-Ts to improve poor outcomes for patients with relapsed T-ALL post-transplant

Alex Rampotas • 16 Apr 2024
EBMT 2024
Acute Lymphoblastic Leukemia Leukemia CAR-T

Alex Rampotas, MD, University College London, London, UK, discusses ongoing projects to develop novel CAR-T products to improve survival outcomes for adult patients with T-cell acute lymphoblastic leukemia (T-ALL) who relapse after stem cell transplantation (SCT). This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alex Rampotas

0:44
The recent FDA approval of ponatinib for Ph+ ALL following success in the PhALLCON trial
Alex Rampotas • 16 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
1:38
The future of CAR-T for hematological malignancies and solid tumors
Alex Rampotas • 15 Feb 2024

Related Videos

2:05
CAR T-cell therapy programs to improve access for patients with leukemia in Mexico
Alberto Olaya-Vargas • 15 Apr 2024
14:43
Current research into post-alloSCT maintenance therapy in AML
Ali Bazarbachi • 3 May 2024
5:20
Targeted therapies in AML: menin, FLT3 and IDH inhibitors
Felicitas Thol • 19 Apr 2024
4:15
Using MRD to guide post-alloSCT treatment decisions in AML
Felicitas Thol • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals